Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official VSports app下载. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

. 2011 Mar 8;108(10):4117-22.
doi: 10.1073/pnas.1016220108. Epub 2011 Feb 18.

"V体育官网入口" Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity

Danfang Zhang  1 , Eva-Maria E Hedlund, Sharon Lim, Fang Chen, Yin Zhang, Baocun Sun, Yihai Cao
Affiliations

Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity

VSports - Danfang Zhang et al. Proc Natl Acad Sci U S A. .

VSports - Abstract

Chemotherapy-induced broad toxicities are the leading cause of the drug-induced mortality in cancer patients VSports手机版. Antiangiogenic drugs (ADs) in combination with chemotherapy are widely used as front-line therapy for the treatment of various human cancers. However, the beneficial mechanisms underlying combination therapy are poorly understood. Here we show that, in several murine tumor models, administration of sunitinib markedly reduced chemotherapy-induced bone marrow toxicity. Intriguingly, in a sequential treatment regimen, delivery of ADs followed by chemotherapy demonstrated superior survival benefits compared with simultaneous administration of two drugs. In murine tumor models, we show that VEGF increased chemotoxicity by synergistically suppressing bone marrow hematopoiesis with cytostatic drugs. These findings shed light on molecular mechanisms by which ADs in combination with chemotherapy produce survival benefits in cancer patients and provide conceptual information guiding future designs of clinical trials, current practice, and optimization of ADs for the treatment of cancer. .

PubMed Disclaimer

"VSports" Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Improvement of survival in a murine melanoma model. (A) Treatment of B16 melanoma-bearing mice (n = 12–15 mice/group) with sunitinib, carboplatin, or vehicle was started when the average tumor size reached 0.4 cm3. Survivals of mice were closely monitored several times per day. (B) Tumor growth rates of sunitinib-, carboplatin-, or vehicle-treated groups (n = 12–15 mice/group). (C) When the average tumor size reached 0.4 cm3, tumor-bearing mice (n = 12–15 mice/group) were treated with sunitinib. At day 6 after treatment, sunitinib-treated mice received carboplatin or carboplatin plus sunitinib until the end of experiments. Vehicle-pretreated group followed by carboplatin was used as a control. (D) Kaplan–Meier survival curve of various treated groups under the regimen described in C. Dashed line marks pretreatment endpoint. (E and F) BM histology of various treated groups described in A–D. Dashed lines enclose bone matrix. (Bar = 100 μm.) (G) Quantification of density of BM cells (20× magnification, eight randomized fields per group). (H–J) RBC (H), hemoglobin (I), and WBC (J) in peripheral blood. *P < 0.05, **P < 0.01, ***P < 0.001. Data are shown as mean ± SEM.
Fig. 2.
Fig. 2.
Tumor growth rate and survival of sunitinib-treated or nontreated VEGF or vector-transfected T241 fibrosarcoma. (A) Growth rates of VEGF-T241 and vector tumors. (B) Kaplan–Meier survival curve of VEGF-T241 and vector-T241 tumor-bearing mice (n = 8–10 mice/group). (C) Growth rates of sunitinib-treated VEGF-T241 and vector tumors. (D) Kaplan–Meier survival curve of sunitinib-treated VEGF-T241 and vector-T241 tumor-bearing mice (n = 8–10 mice/group). (E) BM histology of sunitinib-treated and nontreated groups described in A–D. Dashed lines enclose bone matrix. Arrowheads point to residual hematopoietic islets attached to bone matrix. (Bar = 50 μm.) (F) Quantification of density of BM cells (20× magnification, eight randomized fields per group). (G–I) RBC (G), hemoglobin (H), and WBC (I) in peripheral blood. Blue bars represent tumor-free, black bars represent non-treated, and red bars represent sunitinib-treated. *P < 0.05, ***P < 0.001. Data are shown as mean ± SEM.
Fig. 3.
Fig. 3.
Treatment of VEGF- or vector-T241 tumors with chemotherapeutic drugs. (A) Kaplan–Meier survival curve of carboplatin-treated VEGF-T241 and vector-T241 tumor-bearing mice (n = 8–10 mice/group). Carboplatin exhibited a marked lethal effect on VEGF-tumor bearing mice. (B) Kaplan–Meier survival curve of CTX-treated VEGF-T241 and vector-T241 tumor-bearing mice (n = 8–10 mice/group). (C) BM histology of carboplatin-, CTX-treated, and vehicle-treated groups described in A and B. Dashed lines encircle bone matrix. Arrowheads point to the residue hematopoietic islets attached to the bone matrix. (Bar = 50 μm.) (D) Quantification of density of BM cells (20× magnification, eight randomized fields per group). (E–G) RBC (E), hemoglobin (F), and WBC (G) in peripheral blood. *P < 0.05, **P < 0.01, ***P < 0.001. Data are shown as mean ± SEM.
Fig. 4.
Fig. 4.
Sequential treatment of T241 tumor-bearing mice with sunitinib followed by carboplatin significantly improves survival. (A) Kaplan–Meier survival curve of VEGF-T241 tumor-bearing mice (n = 8–10 mice/group) that received sequential therapy of sunitinib followed by carboplatin or by combination. Simultaneous delivery of both drugs and sunitinib followed by vehicle were used as controls. Sequential regimen of delivery sunitinib followed carboplatin markedly improved survival rates relative to rates in the group that received simultaneous combination therapy. (B) Quantification of density of BM cells (20× magnification, eight randomized fields per group). (C) BM histology of various treated groups described in A. Dashed lines enclose bone matrix. Arrowheads point to residual hematopoietic islets attached to bone matrix. (Bar, 100 μm.) (D–F) RBC (D), hemoglobin (E), and WBC (F) in peripheral blood. *P < 0.05, **P < 0.01, ***P < 0.001. Data are shown as mean ± SEM.
Fig. 5.
Fig. 5.
Survival improvement by sequential treatment of T241 tumor-bearing mice with sunitinib followed by CTX. (A) Kaplan–Meier survival curve of VEGF-T241 tumor-bearing mice (n = 8–10 mice/group) that received sequential therapy of sunitinib followed by CTX or by a combination. Simultaneous delivery of both drugs and sunitinib followed by vehicle was used as control. (B) Quantification of density of BM cells (20× magnification, eight randomized fields per group). (C) BM histology of various treated groups described in A. Dashed lines enclose bone matrix. Arrowheads point to residual hematopoietic islets attached to bone matrix. (Bar, 100 μm.) **P < 0.01. Data are shown as mean ± SEM.
Fig. 6.
Fig. 6.
Schematic diagram of mechanisms underlying antiangiogenic and cytostatic drugs.
See this image and copyright information in PMC

References

    1. Cao Y, Langer R. Optimizing the delivery of cancer drugs that block angiogenesis. Sci Translat Med. 2010;2:15ps13. - PubMed
    1. Cao Y, Zhong W, Sun Y. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin Cancer Biol. 2009;19:338–343. - PubMed (V体育官网入口)
    1. Sarmiento R, D'Andrea MR, Cacciamani F, Salerno F, Gasparini G. Antiangiogenic therapies in breast cancer. Curr Opin Investig Drugs. 2009;10:1334–1345. - PubMed
    1. Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342. - PubMed
    1. Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124. - PubMed

VSports最新版本 - Publication types

MeSH terms

Substances

LinkOut - more resources